

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****Applicants Docket Number:**  
**USAV2001/0133 US PCT****Applicants:**  
**RYNCARZ, A.****Serial No.**  
**08/791,240****Filing Date:**  
**January 30, 1997****Title of Invention:**  
**POSITIVE CONTROLS IN POLYNUCLEOTIDE AMPLIFICATION****CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, Washington, D.C. 20231 at  
(703) 872-9306, onDate of Deposit November 21, 2002Printed Name of Person Signing Certificate Delia CoughlinSignature *Delia Coughlin***Total Number of Pages Sent: 16****Attorney: Michael Schmelzer****Reg. No. 43,093****Group Art Unit: 1634****Examiner: SISSON, B.****TO: Commissioner for Patents**  
**Washington, D.C. 20231**

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Amendment, 37 CFR <u>1.111</u>       | <input type="checkbox"/> Fee Transmittal  |
| <input checked="" type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR                                  |
| <input checked="" type="checkbox"/> Extension of Time Petition           | <input checked="" type="checkbox"/> Other Petition to Withdraw Notice of Appeal |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order           | <input type="checkbox"/> Other  |
| <input type="checkbox"/> Maintenance Fee Transmittal                     |   |

**Receipt Confirmed:**\_\_\_\_\_  
**Signed**\_\_\_\_\_  
**Dated**Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)

NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Received from &lt;9082312626&gt; at 9/10/03 2:26:19 PM [Eastern Daylight Time]

SEP. 10. 2003 1:36PM

AVENTIS US PAT DEPT

NO. 1996 P. 19

P. 1

\* \* \* COMMUNICATION RESULT REPORT ( NOV. 21. 2002 2:06PM ) \* \* \*

TTI AVENTIS US PAT DEPT

FILE MODE	OPTION	ADDRESS (GROUP)	RESULT	PAGE
3085 MEMORY TX		917038729306	OK	16/16

ACTION DUE status-3 mths after reply  
to OA  
DUE DATE 2-21-03  
DKTD BY Ry 11-21-02  
ATTY JMJS

REASON FOR ERROR  
E-1) HANG UP OR LINE FAIL  
E-3) NO ANSWERE-2) BUSY  
E-4) NO FACSIMILE CONNECTION**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**Applicants Docket Number:  
USAV2001/0133 US PCTApplicants:  
RYNCARZ, A.Serial No.  
08/791,240Filing Date:  
January 30, 1997Title of Invention:  
POSITIVE CONTROLS IN POLYNUCLEOTIDE AMPLIFICATION**CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, Washington, D.C. 20231 at  
(703) 872-9306, on

Date of Deposit: November 21, 2002

Printed Name of Person Signing Certificate Delia ConchitaSignature [Signature]

Total Number of Pages Sent: 16

Attorney: Michael Schmelzer  
Reg. No. 43,093Group Art Unit: 1634  
Examiner: SISSON, B.TO: Commissioner for Patents  
Washington, D.C. 20231

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

Received from &lt;9082312626&gt; at 9/10/03 2:26:19 PM [Eastern Daylight Time]



## Auto-Reply Facsimile Transmission



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

TO:

Fax Sender at 9082312626


Fax Information

Date Received:

Total Pages:

11/21/02 1:59:26 PM [Eastern Standard Time]

16 (including cover page)



**ADVISORY:** This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received  
Cover  
Page  
=====>

NOV 21 2002 2:01PM AVENTIS US PAT DEPT		AQ 3035 P. 1	
<b>FAX TRANSMISSION TO THE UNITED STATES PATENT OFFICE</b>			
<b>Applicant's Docket Number</b> USAV2491/0130 US PCT  <b>Applicant:</b> MYNCARZ, A.  <b>Serial No.</b> 00491,240  <b>Filing Date</b> January 30, 1997  <b>Title of Invention:</b> POSITIVE CONTROLS IN POLYNUCLEOTIDE AMPLIFICATION		<div style="border: 1px solid black; padding: 5px;"> <p style="text-align: center; margin: 0;"><b>CERTIFICATE OF TRANSMISSION</b></p> <p style="font-size: small; margin: 0;">I hereby certify that this correspondence is being transmitted via Facsimile to the Commissioner for Patents, Washington, D.C. 20231 on <b>NOV 21 2002</b> at <b>2:01 PM</b>.          Transmitted by <b>Patent Dept.</b>          Signed <b>[Signature]</b></p> </div> <p style="margin-top: 10px;"><b>Total Number of Pages Sent:</b> 16</p> <p><b>Agency:</b> Michael Schneider Reg. No. 40,993</p> <p><b>Group Art Unit:</b> 1634 <b>Examiner:</b> SLESSON, D.</p>	
<b>TO:</b> Commissioner for Patents Washington, D.C. 20231			
Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.			
<input checked="" type="checkbox"/> Amendment, 37 CFR 1.111 <input checked="" type="checkbox"/> Charge deposit account, in duplicate <input checked="" type="checkbox"/> Extension of Time Period <input type="checkbox"/> Issue Fee Transmittal & Advance Order <input type="checkbox"/> Maintenance Fee Transmittal		<input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Decision under 37 CFR <input checked="" type="checkbox"/> Other Petition to Withdraw Notice of Appeal <input type="checkbox"/> Other	
Receipt Confirmed:			
Signed _____		Dated _____	
<p style="font-size: x-small;">Aventis Pharmaceuticals Inc., Route 203-286, P.O. Box 6900, Bridgewater, New Jersey 08807, U.S.A. <a href="http://www.ventis.com">www.ventis.com</a>          NOTICE: The documents accompanying this facsimile transmission are prepared only for the use of the individual or entity named above. If you have not sent this material to them, please inform them immediately by the most rapid means available for the return of the original documents.</p>			
Received from <9082312626> at 9/10/03 2:26:19 PM [Eastern Standard Time]			



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/791,240	01/30/1997	ALEXANDER J. RYNCARZ	BDI-1020	2505
5487	7590	03/25/2003	USAN2001/0133-US-PCT	
ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC ROUTE 202-206 MAIL CODE: D303A BRIDGEWATER, NJ 08807			EXAMINER SISSON, BRADLEY L	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 03/25/2003

Please find below and/or attached an official communication concerning this application or proceeding.

Prepare Petition To Revive - 4/25/03  
File Petition To Revive - 5/25/03  
Petition To Revive/Deadline - 3/25/04

ACTION DUE	↑
DUE DATE	↑
DKTD BY	Jes 3/31/03
ATTY	WEE M.S.

**Notice of Abandonment**

Application No.

087791,240

Examiner

Bradley L. Sisson

Applicant(s)

RYNCARZ, ALEXANDER J.

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

This application is abandoned in view of:

1. ☒ Applicant's failure to timely file a proper reply to the Office letter mailed on 22 May 2002.
  - (a) ☐ A reply was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the period for reply (including a total extension of time of \_\_\_\_\_ month(s)) which expired on \_\_\_\_\_.
  - (b) ☐ A proposed reply was received on \_\_\_\_\_, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection. (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
  - (c) ☐ A reply was received on \_\_\_\_\_ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
  - (d) ☒ No reply has been received.
2. ☐ Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).
  - (a) ☐ The issue fee and publication fee, if applicable, was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
  - (b) ☐ The submitted fee of \$ \_\_\_\_\_ is insufficient. A balance of \$ \_\_\_\_\_ is due.  
The issue fee required by 37 CFR 1.18 is \$ \_\_\_\_\_. The publication fee, if required by 37 CFR 1.18(d), is \$ \_\_\_\_\_.
  - (c) ☐ The issue fee and publication fee, if applicable, has not been received.
3. ☐ Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
  - (a) ☐ Proposed corrected drawings were received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the period for reply.
  - (b) ☐ No corrected drawings have been received.
4. ☐ The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
5. ☐ The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
6. ☐ The decision by the Board of Patent Appeals and Interference rendered on \_\_\_\_\_ and because the period for seeking court review of the decision has expired and there are no allowed claims.
7. ☐ The reason(s) below:

Pursuant to the request of 21 November 2002, the Notice of Appeal has been withdrawn and \$320 has been credited to Deposit Account.



Bradley L. Sisson  
Primary Examiner  
Art Unit: 1634

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.